Heptares And Takeda

Deal Includes GBP4.5 Million Upfront Cash and Equity, Up to GBP60.5 Million in Future Milestone Payments, and Royalties on Product Sales

Older News

CAMBRIDGE, England, April 11, 2011 - Heptares Therapeutics and Takeda Pharmaceutical Company today announced the formation of a two-year drug discovery collaboration focused on a single G-protein coupled receptor (GPCR) that plays an important role in the pathology of central nervous system disorders.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy